AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7486431 — intervention group
Group type: COMPARATOR
Intervention: Nylon suture
Number of subjects: 225
Study 2359575 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring and perinatal nursing support
Number of subjects: 45
Study 2359575 — intervention group
Group type: COMPARATOR
Intervention: Education group
Number of subjects: 45
Study 7380690 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous reinfusion of approximately 900 ml of freeze-preserved blood
Number of subjects: 11
Study 7380690 — intervention group
Group type: COMPARATOR
Intervention: sham reinfusion of 50 ml of saline
Number of subjects: 11
Study 7380690 — intervention group
Group type: COMPARATOR
Intervention: control hematologic levels after erythrocythemia (C3)
Number of subjects: 11
Study 7380690 — intervention group
Group type: COMPARATOR
Intervention: before phlebotomy (C1)
Number of subjects: 11
Study 7380690 — intervention group
Group type: COMPARATOR
Intervention: following restoration of normocythemia (C2)
Number of subjects: 11
Study 30190165 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg TAK-063
Number of subjects: 164
Study 30190165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 28284477 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei rhamnosus Lcr35 (8 × 108 colony‐forming units, n=48), twice daily for 4 weeks
Number of subjects: 94
Study 28284477 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=46), twice daily for 4 weeks
Number of subjects: 94
Study 28284477 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=46)
Number of subjects: 94
Study 28284477 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei rhamnosus Lcr35 (n=48)
Number of subjects: 94
Study 26352940 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol mixed with a liquid meal administered by a nasogastric feeding tube
Number of subjects: 12
Study 26352940 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol mixed with a liquid meal
Number of subjects: 12
Study 26352940 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol in the aqueous phase of the meal
Number of subjects: 12
Study 26352940 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol in the solid bolus of the meal
Number of subjects: 12
Study 26352940 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol as a post prandial marker
Number of subjects: 12
Study 23357167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ig apheresis
Number of subjects: 16
Study 23357167 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 21259004 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 5 mg/day (TS 1) and 10 mg/day (TS ≥ 2), with doses doubled at week 4 if LDL-C target not achieved, for 8 weeks
Number of subjects: 39
Study 21259004 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 5 mg/day (TS 1) and 10 mg/day (TS ≥ 2), for 8 weeks
Number of subjects: 39
Study 21259004 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 5 to 10 mg (TS 1) or 10 to 20 mg (TS ≥ 2) for 8 weeks
Number of subjects: 39
Study 21259004 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 39
Study 19458017 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy supplementation (an extra 475 kcal/d)
Number of subjects: 106
Study 19458017 — intervention group
Group type: COMPARATOR
Intervention: Control group (no high energy supplementation)
Number of subjects: 106
Study 17294706 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional educational
Number of subjects: 160
Study 17294706 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 160
Study 17294706 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECEDE Model
Number of subjects: 160
Study 17294706 — intervention group
Group type: COMPARATOR
Intervention: Usual health center care (Control)
Number of subjects: 160
Study 15646947 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental dentifrice (T)
Number of subjects: 36
Study 15646947 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 36
Study 11443562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous palivizumab (15 mg/kg)
Number of subjects: 21
Study 11443562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous palivizumab (15 mg/kg) with aerosolized ribavirin
Number of subjects: 21
Study 9164909 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with early development of aortic regurgitation
Number of subjects: 315
Study 7963081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar expectancy condition (mothers told their children received a large dose of sugar)
Number of subjects: 35
Study 7963081 — intervention group
Group type: COMPARATOR
Intervention: Control condition (mothers told their sons received a placebo)
Number of subjects: 35
Study 7963081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar expectancy condition
Number of subjects: 35
Study 3445799 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu375
Number of subjects: 2353
Study 3445799 — intervention group
Group type: COMPARATOR
Intervention: Nova-T
Number of subjects: 2353
Study 28666095 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Enteral Immunonutrition (EEIN)
Number of subjects: 78
Study 28666095 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 78
Study 27325341 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet-only decision aid
Number of subjects: 147
Study 27325341 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet with DVD decision aid
Number of subjects: 147
Study 24315293 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.5%
Number of subjects: 400
Study 24315293 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.1%
Number of subjects: 400
Study 24315293 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01%
Number of subjects: 400
Study 24315293 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall increase in SE
Number of subjects: 400
Study 24260170 — intervention group
Group type: COMPARATOR
Intervention: Green tea consumption
Number of subjects: 4808
Study 24260170 — intervention group
Group type: COMPARATOR
Intervention: Rock tea consumption
Number of subjects: 4808
Study 19882171 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd‐p53 combined with fSRT
Number of subjects: 40
Study 19882171 — intervention group
Group type: COMPARATOR
Intervention: fSRT alone
Number of subjects: 40
Study 18247220 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Injury (EI) patients
Number of subjects: 79
Study 18247220 — intervention group
Group type: COMPARATOR
Intervention: Chronic Pain (CP) patients
Number of subjects: 79
Study 18247220 — intervention group
Group type: COMPARATOR
Intervention: Traumatic Brain Injury (TBI) patients
Number of subjects: 79
Study 17138773 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg nightly for 4 weeks
Number of subjects: 410
Study 17138773 — intervention group
Group type: COMPARATOR
Intervention: Placebo nightly for 4 weeks
Number of subjects: 410
Study 12955028 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 0
Study 12955028 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex steroid treatment (testosterone for men, oestrogen/progestin for women)
Number of subjects: 0
Study 12955028 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11144863 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (50 min of cycle ergometry at 70‐110% of critical power)
Number of subjects: 8
Study 11144863 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no cycling performed)
Number of subjects: 8
Study 11144863 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 8
Study 9200306 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon mono-therapy
Number of subjects: 0
Study 9200306 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin combination therapy
Number of subjects: 0
Study 9200306 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged interferon therapy
Number of subjects: 0
Study 7694879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (with or without azathioprine)
Number of subjects: 20
Study 7694879 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 20
Study 7694879 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 20
Study 3083211 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/d of sorbinil
Number of subjects: 39
Study 3083211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 29661477 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP) <60 mm Hg
Number of subjects: 3417
Study 29661477 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP) 60-69 mm Hg
Number of subjects: 3417
Study 29661477 — intervention group
Group type: COMPARATOR
Intervention: Diastolic blood pressure (DBP) 80-89 mm Hg
Number of subjects: 3417
Study 29661477 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP) <70 mm Hg
Number of subjects: 3417
Study 29661477 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP) ≥70 mm Hg with systolic blood pressure (SBP) <120 mm Hg
Number of subjects: 3417
Study 27431451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral arm remote ischemic postconditioning (RIPC) twice a day for 6 months
Number of subjects: 100
Study 27431451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral arm remote ischemic postconditioning (RIPC)
Number of subjects: 100
Study 24343119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight blood pressure control (systolic BP target <130 mm Hg)
Number of subjects: 1111
Study 24343119 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (systolic BP target <140 mm Hg)
Number of subjects: 1111
Study 22804619 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-G cannula
Number of subjects: 80
Study 22804619 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-G cannula
Number of subjects: 80
Study 21127697 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower seed extract (SSE) 70 mg/day for 12 weeks
Number of subjects: 92
Study 21127697 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 92
Study 18492267 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily interruption of sedation (DIS)
Number of subjects: 74
Study 18492267 — intervention group
Group type: COMPARATOR
Intervention: Sedation algorithms (SA)
Number of subjects: 74
Study 16014059 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) for 24 weeks
Number of subjects: 40
Study 16014059 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 40
Study 12457373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost methods used in economic evaluations
Number of subjects: 45
Study 12457373 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis of cost data
Number of subjects: 45
Study 10621928 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (5 mg/kg)
Number of subjects: 0
Study 10621928 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study 7594127 — intervention group
Group type: COMPARATOR
Intervention: Usual-protein group
Number of subjects: 840
Study 7594127 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein group
Number of subjects: 840
Study 7594127 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-protein group
Number of subjects: 840
Study 2030877 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipelle endometrial sampling
Number of subjects: 40
Study 2030877 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipelle biopsy
Number of subjects: 40
Study 7141389 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon
Number of subjects: 20
Study 7141389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29943060 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DP
Number of subjects: 45
Study 29943060 — intervention group
Group type: COMPARATOR
Intervention: VIR
Number of subjects: 45
Study 29943060 — intervention group
Group type: COMPARATOR
Intervention: MDCT
Number of subjects: 45
Study 28934531 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension (EXT; 1.5‐hour increase in time in bed from HAB)
Number of subjects: 76
Study 28934531 — intervention group
Group type: COMPARATOR
Intervention: Prescribed habitual sleep (HAB; sleep time set to match baseline)
Number of subjects: 76
Study 27179184 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths-based case management (SBCM) service
Number of subjects: 1276
Study 27179184 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual PRS (Control)
Number of subjects: 1276
Study 24399094 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counseling session for approximately 10 min
Number of subjects: 0
Study 24399094 — intervention group
Group type: COMPARATOR
Intervention: Control group (received a booklet for general diabetes prevention)
Number of subjects: 0
Study 22460438 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst group (thawed and cultured in sequential media until blastocyst stage)
Number of subjects: 134
Study 22460438 — intervention group
Group type: COMPARATOR
Intervention: Cleavage group (thawed embryos in cleavage stage)
Number of subjects: 134
Study 19687336 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD 30 mg/m2 followed by docetaxel 60 mg/m2 every 21 days (n = 378)
Number of subjects: 751
Study 19687336 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 (n = 373)
Number of subjects: 751
Study 17578957 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA with propofol + 7.5 ng/mL remifentanil (LMA-PR)
Number of subjects: 24
Study 17578957 — intervention group
Group type: EXPERIMENTAL
Intervention: LT with propofol + 7.5 ng/mL remifentanil (LT-PR)
Number of subjects: 24
Study 17578957 — intervention group
Group type: COMPARATOR
Intervention: LMA with propofol + saline (LMA-P)
Number of subjects: 24
Study 17578957 — intervention group
Group type: COMPARATOR
Intervention: LT with propofol + saline (LT-P)
Number of subjects: 24
Study 15279343 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg lornoxicam
Number of subjects: 56
Study 15279343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 11773166 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m² plus Irinotecan 175 mg/m²
Number of subjects: 92
Study 11773166 — intervention group
Group type: COMPARATOR
Intervention: Raltitrexed 3 mg/m²
Number of subjects: 92
Study 11773166 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin/irinotecan after cross-over
Number of subjects: 92
Study 11773166 — intervention group
Group type: COMPARATOR
Intervention: Raltitrexed after cross-over
Number of subjects: 92
Study 9419196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg orally twice daily
Number of subjects: 81
Study 9419196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 8127329 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol (50 mg per day)
Number of subjects: 29133
Study 8127329 — intervention group
Group type: EXPERIMENTAL
Intervention: beta carotene (20 mg per day)
Number of subjects: 29133
Study 8127329 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol
Number of subjects: 29133
Study 8127329 — intervention group
Group type: EXPERIMENTAL
Intervention: beta carotene
Number of subjects: 29133
Study 8127329 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29133
Study 2916913 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative physical therapy
Number of subjects: 115
Study 2916913 — intervention group
Group type: COMPARATOR
Intervention: No physical therapy (Control)
Number of subjects: 115
Study 791329 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol 400 mg/d
Number of subjects: 30
Study 791329 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol 800 mg/d
Number of subjects: 30
Study 30953546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery learning and deliberate practice (ML + DP)
Number of subjects: 160
Study 30953546 — intervention group
Group type: COMPARATOR
Intervention: Self-guided practice
Number of subjects: 160
Study 27444848 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty (TKA)
Number of subjects: 2080
Study 25590939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotonovela Condition (FNC)
Number of subjects: 110
Study 25590939 — intervention group
Group type: COMPARATOR
Intervention: Usual Information Condition (UIC)
Number of subjects: 110
Study 22882879 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to a radio-broadcast while driving in high-complexity traffic
Number of subjects: 46
Study 22882879 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to a radio-broadcast while driving in low-complexity traffic
Number of subjects: 46
Study 22882879 — intervention group
Group type: COMPARATOR
Intervention: Driving in silence (Control group)
Number of subjects: 46
Study 20557973 — intervention group
Group type: EXPERIMENTAL
Intervention: Repressive coping style (n=30)
Number of subjects: 107
Study 20557973 — intervention group
Group type: COMPARATOR
Intervention: Low-anxious coping style (n=25)
Number of subjects: 107
Study 20557973 — intervention group
Group type: COMPARATOR
Intervention: High-anxious coping style (n=31)
Number of subjects: 107
Study 20557973 — intervention group
Group type: COMPARATOR
Intervention: Defensive high-anxious coping style (n=21)
Number of subjects: 107
Study 19597668 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimuli (music and voice message)
Number of subjects: 30
Study 19597668 — intervention group
Group type: COMPARATOR
Intervention: No auditory stimuli (Control Group)
Number of subjects: 30
Study 17470884 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg x day(‐1) po, followed by 200 mg po bid for three days)
Number of subjects: 80
Study 15305252 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary block (A)
Number of subjects: 80
Study 15305252 — intervention group
Group type: COMPARATOR
Intervention: Humeral block (H)
Number of subjects: 80
Study 11668227 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Appendectomy (OA)
Number of subjects: 75
Study 11668227 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Appendectomy (LA)
Number of subjects: 75
Study 11668227 — intervention group
Group type: EXPERIMENTAL
Intervention: Needlescopic Appendectomy (nLA)
Number of subjects: 75
Study 9667264 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 every 4 weeks
Number of subjects: 432
Study 9667264 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 every 4 weeks and vinorelbine 25 mg/m2 weekly
Number of subjects: 432
Study 8205778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing amalgam
Number of subjects: 415
Study 8205778 — intervention group
Group type: COMPARATOR
Intervention: Conventional amalgam
Number of subjects: 415
Study 2645420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal papaverine (30 mg. per ml.)
Number of subjects: 15
Study 2645420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal prostaglandin E1 (10 mcg. per ml.)
Number of subjects: 15
Study 2645420 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 15
Study 2645420 — intervention group
Group type: COMPARATOR
Intervention: Intracorporeal prostaglandin E1
Number of subjects: 15
Study 31043808 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic erlotinib ($1460.25 per 30 days)
Number of subjects: 1979
Study 31043808 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic cetuximab ($275.80 per 100 mg)
Number of subjects: 1979
Study 31043808 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic cetuximab at reduced costs ($129.39 and $63.51)
Number of subjects: 1979
Study 28253845 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy (MT) consisting of sleep education/restriction, psycho-education, eurythmy- and painting-therapy
Number of subjects: 126
Study 28253845 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (CT) consisting of multimodal therapy (MT) plus aerobic training (AT)
Number of subjects: 126
Study 28253845 — intervention group
Group type: COMPARATOR
Intervention: Standard aerobic treatment (AT)
Number of subjects: 126
Study 26188537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS) 6.5 × 10(9) CFU, 3 times daily for 12 weeks
Number of subjects: 30
Study 26188537 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (no LcS)
Number of subjects: 30
Study 23429924 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-based collaborative care
Number of subjects: 364
Study 23429924 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care
Number of subjects: 364
Study 22026403 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and Lifestyle Advice Group
Number of subjects: 2180
Study 22026403 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Group
Number of subjects: 2180
Study 19060419 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 823
Study 19060419 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 823
Study 12972387 — intervention group
Group type: EXPERIMENTAL
Intervention: 5520 cGy
Number of subjects: 67
Study 12972387 — intervention group
Group type: EXPERIMENTAL
Intervention: 5940 cGy
Number of subjects: 67
Study 12972387 — intervention group
Group type: EXPERIMENTAL
Intervention: 6375 cGy
Number of subjects: 67
Study 10189455 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose breath-hold gadolinium-enhanced MR angiography with 20 mL of gadopentetate dimeglumine (average dose, 0.11 mmol/kg)
Number of subjects: 60
Study 7785485 — intervention group
Group type: EXPERIMENTAL
Intervention: smoking cessation plus exercise
Number of subjects: 20
Study 7785485 — intervention group
Group type: COMPARATOR
Intervention: smoking cessation with frequency contact control
Number of subjects: 20